|
|
Post by bones1026 on May 10, 2021 21:18:58 GMT -5
Still don’t understand that 25M spike in shorts..they always appear to be one step ahead, but I just can’t see their angle at this point..put Afrezza completely aside for now, I still think with UTHR and and RLS, we’re “worth” more than 1B now..and Afrezza is apparently pretty good if you can get it, and know how to use it properly 😉
So what do they know that we don’t?
|
|
|
|
Post by cretin11 on May 10, 2021 21:47:23 GMT -5
UTHR is legit. The street probably assigns little to no value to the RLS collaboration. We’ve stopped pushing Afrezza. If Afrezza can make a comeback - ok, comeback isn’t the right word - or if VDEX can make Afrezza successful; and/or if RLS actually materializes, then shorts might decide to make their orderly exit.
|
|
|
|
Post by sportsrancho on May 10, 2021 22:17:31 GMT -5
UTHR is legit. The street probably assigns little to no value to the RLS collaboration. We’ve stopped pushing Afrezza. If Afrezza can make a comeback - ok, comeback isn’t the right word - or if VDEX can make Afrezza successful; and/or if RLS actually materializes, then shorts might decide to make their orderly exit. The only negative I can see at the moment is we’re going to miss the covenants. Unknown consequences. I think once we /United therapeutics gets the go ahead from the FDA for TrepT we are off. |
|
|
|
Post by prcgorman2 on May 10, 2021 22:32:07 GMT -5
History will tell you it's going down. And so will the shorts... |
|
|
|
Post by falconquest on May 11, 2021 6:22:48 GMT -5
UTHR is legit. The street probably assigns little to no value to the RLS collaboration. We’ve stopped pushing Afrezza. If Afrezza can make a comeback - ok, comeback isn’t the right word - or if VDEX can make Afrezza successful; and/or if RLS actually materializes, then shorts might decide to make their orderly exit. Are we getting to a point where Afrezza can't be successful without VDEX? |
|
|
|
Post by prcgorman2 on May 11, 2021 6:23:28 GMT -5
Nope
|
|
|
|
Post by falconquest on May 11, 2021 6:28:39 GMT -5
UTHR is legit. The street probably assigns little to no value to the RLS collaboration. We’ve stopped pushing Afrezza. If Afrezza can make a comeback - ok, comeback isn’t the right word - or if VDEX can make Afrezza successful; and/or if RLS actually materializes, then shorts might decide to make their orderly exit. The only negative I can see at the moment is we’re going to miss the covenants. Unknown consequences. I think once we /United therapeutics gets the go ahead from the FDA for TrepT we are off. I hate to say it but there's always that next catalyst just six months away that will finally drive the share price forward. It's been the same story for years. Not saying TrepT won't help Mannkind's bottom line but will any potential SP boost be offset by shorting prior to approval? I guess we shall see. |
|
|
|
Post by Clement on May 11, 2021 9:01:26 GMT -5
UTHR is legit. The street probably assigns little to no value to the RLS collaboration. We’ve stopped pushing Afrezza. If Afrezza can make a comeback - ok, comeback isn’t the right word - or if VDEX can make Afrezza successful; and/or if RLS actually materializes, then shorts might decide to make their orderly exit. The only negative I can see at the moment is we’re going to miss the covenants. Unknown consequences. I think once we /United therapeutics gets the go ahead from the FDA for TrepT we are off. I don't understand the part about "miss the covenants". That was restructured recently, right? See the following from April 26. For now, no consequences. finance.yahoo.com/news/mannkind-reduces-legacy-debt-approximately-130000144.htmlMannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche The MidCap Credit Facility was amended to modify several terms, including: (i) increasing the funds available in tranche 3, if drawn by the Company, from $25.0 million to $60.0 million; (ii) revising the conditions to drawing tranche 3, including milestone conditions associated with Tyvaso DPI™; (iii) providing for an exit fee of $1.0 million in connection with the prepayment described below in lieu of the existing prepayment penalty and exit fees; (iv) removing the requirement to issue a warrant to purchase shares of MannKind’s common stock upon the drawdown of tranche 3; (v) decreasing the interest rate on the remaining outstanding debt; (vi) extending the interest-only period and maturity of term loans under the MidCap Credit Facility; (vii) reducing the minimum cash covenant from $30.0 million to $10.0 million, effective immediately, and eliminating such covenant in the event that Tyvaso DPI™ is approved by the FDA; (viii) eliminating the requirement to test compliance with the minimum Afrezza net revenue covenant so long as the Company has $90.0 million or more of unrestricted cash; (ix) permitting the Company to make certain acquisitions subject to certain conditions; and (x) permitting the Company to make investments of up to an additional $9.0 million so long as the Company has $90.0 million or more of unrestricted cash following such investment. In connection with the amendment of the MidCap Credit Facility, MannKind prepaid $10.0 million in cash to reduce the principal balance under the MidCap Credit Facility from $50.0 million to $40.0 million. |
|
|
|
Post by mango on May 11, 2021 12:21:33 GMT -5
This year’s looking good you guys.
🥭 Tyvaso DPI FDA approval Q4 this year
🥭 Afrezza Pediatrics Phase 3 clinical trial this year
🥭 Clofazimine Phase 1 this year
🥭 Royalties from Thyquidity Co-Promote w/ Vertice Pharma starts NOW
🥭 BluHale Pro Launch this year
🥭 Afrezza European Union filing this year—NO additional clinical trials required!
🥭 Afrezza Australia approval this year
🥭 Afrezza clinical trial for gestational diabetes incoming
🥭 Potentially over $100M in annual royalties from partner $UTHR for Tyvaso DPI
🥭 We have over $300M in cash—enough to get us to cash flow break even!
🥭 Manufacturing facility lease buy back incoming
🥭 Cannabis partner Receptor Life Sciences Phase 1 incoming
🥭 Pipeline advancement
🥭 New partnerships
🥭 Afrezza India Clinical Trial starts this year
🥭 Further Debt Reduction
🥭 New Afrezza scientific publications this year
🥭 A second UT molecule incoming
|
|
|
|
Post by bones1026 on May 11, 2021 13:20:40 GMT -5
UTHR is legit. The street probably assigns little to no value to the RLS collaboration. We’ve stopped pushing Afrezza. If Afrezza can make a comeback - ok, comeback isn’t the right word - or if VDEX can make Afrezza successful; and/or if RLS actually materializes, then shorts might decide to make their orderly exit. The only negative I can see at the moment is we’re going to miss the covenants. Unknown consequences. I think once we /United therapeutics gets the go ahead from the FDA for TrepT we are off. Didn’t our restructuring deal with that? Wasn’t that why we paid off 49M of higher interest loans? |
|
|
|
Post by stockwhisperer on May 11, 2021 14:08:42 GMT -5
Not understanding any negative covenant issues based on changes made... The MidCap Credit Facility was amended to modify several terms, including: (i) increasing the funds available in tranche 3, if drawn by the Company, from $25.0 million to $60.0 million; (ii) revising the conditions to drawing tranche 3, including milestone conditions associated with Tyvaso DPI™; (iii) providing for an exit fee of $1.0 million in connection with the prepayment described below in lieu of the existing prepayment penalty and exit fees; (iv) removing the requirement to issue a warrant to purchase shares of MannKind’s common stock upon the drawdown of tranche 3; (v) decreasing the interest rate on the remaining outstanding debt; (vi) extending the interest-only period and maturity of term loans under the MidCap Credit Facility; (vii) reducing the minimum cash covenant from $30.0 million to $10.0 million, effective immediately, and eliminating such covenant in the event that Tyvaso DPI™ is approved by the FDA; (viii) eliminating the requirement to test compliance with the minimum Afrezza net revenue covenant so long as the Company has $90.0 million or more of unrestricted cash; (ix) permitting the Company to make certain acquisitions subject to certain conditions; and (x) permitting the Company to make investments of up to an additional $9.0 million so long as the Company has $90.0 million or more of unrestricted cash following such investment. In connection with the amendment of the MidCap Credit Facility, MannKind prepaid $10.0 million in cash to reduce the principal balance under the MidCap Credit Facility from $50.0 million to $40.0 million.
|
|
|
|
Post by sportsrancho on May 11, 2021 14:23:05 GMT -5
The only negative I can see at the moment is we’re going to miss the covenants. Unknown consequences. I think once we /United therapeutics gets the go ahead from the FDA for TrepT we are off. Didn’t our restructuring deal with that? Wasn’t that why we paid off 49M of higher interest loans? So long as the Company has $90.0 million or more of unrestricted cash. |
|
|
|
Post by hellodolly on May 11, 2021 14:36:44 GMT -5
mango India trials might be delayed this year but, could be a surprise if they can get it initiated despite the outbreak of C19 and all of the medical resources being funneled into that direction. Great list!!
|
|
|
|
Post by phdedieu12 on May 11, 2021 14:55:14 GMT -5
UTHR is legit. The street probably assigns little to no value to the RLS collaboration. We’ve stopped pushing Afrezza. If Afrezza can make a comeback - ok, comeback isn’t the right word - or if VDEX can make Afrezza successful; and/or if RLS actually materializes, then shorts might decide to make their orderly exit. If VDEX could make Afrezza successful we would already know..... The fact that it hasn't tells you everything you need to know |
|
|
|
Post by spikespiegel on May 11, 2021 15:02:40 GMT -5
mango India trials might be delayed this year but, could be a surprise if they can get it initiated despite the outbreak of C19 and all of the medical resources being funneled into that direction. Great list!! The Link for the India Trial, so we dont miss a update |
|
